Oramed Pharmaceuticals (ORMP) Share-based Compensation (2010 - 2026)

Oramed Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Share-based Compensation fell 20.69% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 4.2% YoY) and the FY2025 annual result came in at $5.2 million, up 28.86% from the prior year.
• Share-based Compensation was $1.7 million for Q1 2026 at Oramed Pharmaceuticals, up from $1.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $2.9 million in Q3 2022 and bottomed at -$8.2 million in Q4 2022.
• A 5-year average of $417294.1 and a median of $1.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation slumped 194.05% — and 2024, when it jumped 641.04%.
• Oramed Pharmaceuticals' Share-based Compensation stood at -$8.2 million in 2022, then surged by 116.72% to $1.4 million in 2023, then declined by 11.05% to $1.2 million in 2024, then increased by 18.75% to $1.4 million in 2025, then climbed by 20.22% to $1.7 million in 2026.
• Business Quant data shows ORMP's Share-based Compensation at $1.7 million in Q1 2026, $1.4 million in Q4 2025, and $719000.0 in Q3 2025.